| Biomarker ID | 1033 |
| PMID | 23265571 |
| Year | 2013 |
| Biomarker | Bone-specific alkaline phosphatase |
| Biomarker Basis | Concentration Based (ug/L) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated in patients with PCa treated with with Risedronate (Placebo: 60.29 ± 10.28; Risedronate: 9.94 ± 6.95) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Placebo vs Risedronate (after 24 months) |
| Type of Biomarker | Predictive |
| Cohort | 104 patients were accrued between 2004 and 2007, with 52 in each arm. (placebo and risedronate). After 24 months info available for: Placebo (n=25), Risedronate (n=22) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p =0.0002 |
| Method Used | LUNAR DEXA |
| Clinical | Yes |
| Remarks | Bone Mineral Density biomarkers are used for evaluating the effect of Risedronate |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |